In the E.U., secukinumab is edging closer to approval for use in pediatric patients with juvenile idiopathic arthritis (JIA), specifically those with enthesitis-related arthritis (ERA) and juvenile psoriatic arthritis (PsA). In May, the Committee for Medicinal Products for Human Use of the European Medicines Agency issued a positive opinion on expanding its indications.
The FDA has approved the use of secukinumab for pediatric patients with enthesitis-related arthritis and psoriatic arthritis, after research showed a longer time to disease flare than placebo.
A posthoc analysis confirms patients with active psoriatic arthritis (PsA) taking secukinumab experience improvement in all signs and symptoms of PsA as measured by the GRAPPA-OMERACT disease activity core domains.
In a comparison study, subcutaneous mirikizumab proved superior to subcutaneous in achieving skin clearance in patients with plaque psoriasis…
In June, the FDA approved secukinumab to treat non-radiographic axial spondyloarthritis after data from a clinical trial demonstrated its efficacy…
In a phase 3, comparator study in adults with plaque psoriasis, patients taking
risankizumab achieved greater skin clearance than those taking secukinumab…
The Scottish Medicines Consortium has released a detailed advice document recommending risankizumab for treating adults with psoriasis…
Secukinumab therapy proved safe and effective for psoriatic arthritis patients with multiple co-morbidities and long treatment histories, according to recent research…
In a four-year study, patients with active psoriatic arthritis (PsA) experienced sustained improvement in PsA signs and symptoms on secukinumab…
In a long-term study, secukinumab proved safe and effective for treating ankylosing spondylitis…